Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,286.75
    -2,610.52 (-3.04%)
     

  • CMC Crypto 200

    1,262.46
    -95.55 (-7.03%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

Today's Research Reports on GeneNews, Titan Medical, Neovasc and Trillium Therapeutics

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

GeneNews Limited
https://rdinvesting.com/news/?ticker=GEN.TO

Titan Medical Inc.
https://rdinvesting.com/news/?ticker=TMD.TO

Neovasc Inc.
https://rdinvesting.com/news/?ticker=NVCN.TO

Trillium Therapeutics Inc.
https://rdinvesting.com/news/?ticker=TRIL.TO

GeneNews had no change Friday, to close the day at $0.055. The stock recorded a trading volume of 160,000 shares, which was above its three months average volume of 105,950 shares. In the last year, GeneNews' shares have traded in a range of 0.05 - 0.24. The share price has gained 10% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.063 is lower than its 200-day moving average of $0.081. Shares of GeneNews have fallen approximately 73.91 percent year-to-date.

ADVERTISEMENT

Access RDI's GeneNews Limited Research Report at:
https://rdinvesting.com/news/?ticker=GEN.TO

On Friday, shares of Titan Medical recorded a trading volume of 3,411 shares, which was below the three months average volume of 44,398 shares. The stock ended the day 1.1% higher at $2.75. The share price has fallen 86.52% from its 52 week high with a 52 week trading range of 2.22 - 20.40. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.62 is lower than its 200-day moving average of $5.92. Shares of Titan Medical have fallen approximately 75.88 percent year-to-date.

Access RDI's Titan Medical Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TMD.TO

Neovasc’s stock moved 5.36% lower Friday, to close the day at $3.53. The stock recorded a trading volume of 75,615 shares, which was above its three months average volume of 29,283 shares. In the last year, Neovasc's shares have traded in a range of 2.90 - 223.00. The share price has gained 21.72% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.51 is lower than its 200-day moving average of $5.98. Shares of Neovasc have fallen approximately 95.29 percent year-to-date.

Access RDI's Neovasc Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVCN.TO

On Friday, shares of Trillium Therapeutics recorded a trading volume of 4,060 shares, which was above the three months average volume of 2,740 shares. The stock ended the day 3.9% lower at $7.40. The share price has fallen 55.95% from its 52 week high with a 52 week trading range of 6.27 - 16.80. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.54 is lower than its 200-day moving average of $7.98. Shares of Trillium Therapeutics have fallen approximately 18.68 percent year-to-date.

Access RDI's Trillium Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TRIL.TO

Our Actionable Research on GeneNews Limited (TSX:GEN.TO), Titan Medical Inc. (TSX:TMD.TO), Neovasc Inc. (TSX:NVCN.TO) and Trillium Therapeutics Inc. (TSX:TRIL.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com